Sen. Tom Cotton Addresses Chinese Drug Imports
During a recent event with Breitbart News, Senator Tom Cotton from Arkansas emphasized the dangers posed by China, arguing that the U.S. should not approve Chinese medicines while burdening American companies with excessive regulations.
The conversation revealed a startling truth: American regulations allow Chinese firms to produce counterfeit and synthetic versions of U.S. medications. Matthew Boyle, the event’s moderator, described these products as containing “cheap, strange ingredients that we don’t understand.”
Despite the situation, these items still receive approval from the FDA, which Cotton believes is unacceptable.
“Unfortunately, once again, China has taken over many drug markets through illegal methods. We’re not just talking about advanced medications; many basic drugs like ibuprofen, acetaminophen, penicillin, and heparin are involved,” he stated. “China has been monopolizing this space for decades, and that poses a significant risk.”
“We often take for granted that we can just grab a bottle of ibuprofen from Walmart if needed. But if China decides to restrict access, it could lead to serious issues—like if kids can’t get antibiotics because of a blockage, that’s a major concern.”
There’s another layer of worry here. Cotton pointed out that compounded drugs, which aren’t mass-produced, could be harmful. “If you or someone close to you has a condition and opts for a cheaper combination medication with unreliable Chinese ingredients, you might unwittingly put your health at risk. There have even been instances where such drugs caused illness or worse,” he remarked. “We really need to take a strong stand against these contaminated products entering the U.S.”
He also discussed the potential consequences if relations deteriorated and China stopped exporting medications to the U.S.
“This isn’t hypothetical. Back in 2010, China threatened to pull rare earth elements from Japan due to an island dispute. In 2020, amidst the early pandemic, China even suggested withholding essential supplies like gloves, masks, and basic medical equipment when I raised concerns about their role in the outbreak,” Cotton said. He concluded that China would likely do it again.
“They’ve shown us this through their words and actions,” he added. He believes the U.S. needs to enhance its own production capabilities or seek sources from more reliable partners.
Cotton argued that the unnecessary bureaucratic obstacles in the U.S. must be removed.
“We shouldn’t be endorsing Chinese drugs while our own pharmaceutical companies struggle under layers of red tape that hinder their ability to establish new manufacturing sites,” Cotton asserted.
He recommended expediting clinical trials and getting more drugs on the market, leveraging the buying power of U.S. government programs like Medicare, Medicaid, and the Veterans Administration. “That’s significant purchasing power, and it shouldn’t support Chinese drug firms when American manufacturers could provide comparable products,” he concluded.
